A new kind of scan for children with low grade glioma
Original title: Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to see if the scan is safe and useful.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a special scan called 18F-Fluciclovine PET-MRI in children with a low grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary.
Who this trial is for. This study is for children with a low grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. It tests whether a scan using 18F-Fluciclovine is useful and safe. Children get the scan before treatment starts, then again at 3 months and 1 year.
Where it stands. This trial has not reported results. The team is comparing what the new scan shows with what regular MRI scans show over time. They want to know if the scan helps doctors manage care. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Scans help doctors see what a tumor is doing. This study asks if this scan can add useful information. A family whose child fits could ask their care team about it.
What it doesn't mean: This does not mean the scan is proven. A trial is a test, not care you can count on. Joining does not promise any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.